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Background. Regular clinic attendance for antiretroviral (ARV) drug reﬁlls is important for successful clinical outcomes in HIV
management. Methods. Clinic attendance for ARV drug reﬁlls and medication adherence using a clinic-based pill count in 392
adult patients receiving antiretroviral therapy (ART) in a district hospital in Uganda were prospectively monitored over a 28-week
period. Results. Of the 2267 total scheduled clinic visits, 40 (1.8%) were missed visits. Among the 392 clients, 361 (92%) attended
all appointments for their reﬁlls (regular attendance). Clinic attendance for reﬁlls was statistically signiﬁcantly associated with
medication adherence with regular attendant clients having about fourfold greater odds of achieving optimal (≥95%) medication
adherence [odds ratio(OR) = 3.89, 95%CI: 1.48 to 10.25,exact P = .013].In multivariateanalysis,clientsin age category 35 years
andbelow were less likelyto achieve regular clinicattendance.Conclusion. Monitoringofclinicattendance maybe anobjective and
eﬀective measure and could be a useful adjunct to an adherence measure such as pill counting in resource-constrained settings.
Wherehumanresource constraintsdonotallowpill countsorother time-consumingmeasures,thenmonitoringclinicattendance
and acting on missed appointments may be an eﬀective proxy measure.
1.Introduction
HIV aﬀects an estimated 33 million worldwide with approx-
imately 22 million of these in subSaharan Africa [1]. HIV
prevalenceisestimatedat5–15%inmostsubSaharanAfrican
countries with Uganda having an estimated prevalence of
5.4% among adults [1]. The widespread use of ARVs in the
treatment of HIV has led to signiﬁcant decreases in HIV-
related morbidity and mortality worldwide [2]. Access to
ART has been scaled up throughout the country since the
rolloutoffreeARTinUgandain2004[3].Therearecurrently
336 accredited ART sites across the country and about
190,000 people are now accessing ART countrywide [4].
Nonadherence is the most common cause of treatment
failure and the development of resistance to ARVs [5].
Though factors such as antiretroviral regimen potency and
medication adherence all play a role in the development
of antiretroviral medication resistance [6], the goal of HIV
therapy is to achieve near-perfect adherence leading to
sustained virologic suppression [7]. As more people gain
access to ART, there is the need to ﬁnd simple, eﬃcient
and replicable ways of assessing and maintaining these near-
perfect levels of adherence to ensure sustained virologic
suppression.
Adherence to ART is measured by a variety of methods
with the most commonly used methods being self-reporting
by patients, pill counts, review of pharmacy records and
Medication Event Monitoring System (MEMS) caps [8].
There are also biochemical measures, such as viral loads
and therapeutic drug monitoring. All these methods have
their shortcomings. No gold standard has as yet been
found for evaluating adherence to medication to date [9].
Measuring medication adherence in clinical settings has not
always been easy because common methods such as pill2 AIDS Research and Treatment
c o u n t sa r en o to b j e c t i v ee n o u g ha n dt h em o r ea c c u r a t e
measures of adherence such as drug-level monitoring are
expensive, can be inconvenient, diﬃcult to implement in
resource poor settings, and not very relevant since it can
only practically be done intermittently and appears to be
only sensitive for identifying very low levels of adherence
[10]. However, patients’ clinic attendance for medication
reﬁlls can easily be monitored by the health staﬀ,e v e ni n
resource-constrained settings [11, 12]. Inconsistent atten-
dance may help identify patients in need of adherence
counselling [13]. In resource-rich countries, poor clinic
attendance has been shown to be correlated with mortality
[9]. Missed appointments have also been shown to be a
strong predictor for virological failure [14, 15]. The Inter-
national Network for the Rational Use of Drugs Initiative
on Adherence to Antiretroviral Therapy (INRUD-IAA) [16]
has recently identiﬁed, tested and validated against clinical
outcomes, core indicators for adherence to ARV medicines,
and treatment defaulting, one of which includes patient
attendance at appointments [17]. Consistent or regular
clinic attendance plays a key role in prolonging life and
enhancing quality of life for people living with HIV/AIDS
[18].
Few studies have assessed ART adherence based on
clinic attendance [17, 19]. Previous studies have shown that
clinic attendance is associated with medication adherence
in patients with chronic illness [20, 21]. Appointment
attendancehasalsobeenoftenusedasaproxyformedication
adherence in nonHIV/AIDS treatment settings [22, 23].
Most of the little published data evaluating the medication
adherence—clinic attendance relationship in HIV patients
on ART have been from cross-sectional surveys and retro-
spective collection of data. A cross-sectional questionnaire
survey conducted in India reported a statistically signiﬁ-
cant relationship between 100% medication adherence and
regular followup attendance [24]. Giordano and colleagues
[25] in their retrospective cohort study reported a signiﬁcant
relationship between regular clinic attendance or retention
in care and antiretroviral medication adherence. In another
retrospective cohort study of 16 HIV/AIDS treatment facil-
ities in the eastern part of Africa, it was demonstrated
that dispensing-based adherence, self-reported adherence,
and consistent visit attendance were signiﬁcantly correlated
[17]. The relationships reported have been as a result
of brief cross-sectional measurements and extraction of
data from records, therefore they do not provide enough
information about the longitudinal relationship between
clinic attendance and ART adherence.
In our prospective study, we set out to assess clinic
attendance for medication reﬁlls amongst an antiretroviral
treatment cohort, determine the association between clinic
attendance and adherence to ART and assess the factors
associated with optimal medication adherence and regular
clinic attendance.
2.Materialsand Methods
2.1. Study Area. The study was conducted in Kayunga
Hospital located in the Kayunga District of central Uganda.
Kayunga hospital is a 123 bed capacity health facility located
in a rural setting. It receives ARVs from Makerere University
Walter Reed Project (MUWRP) and the Uganda Ministry of
Health. This site is a government accredited ART site and
provides ARVs and ART care free of charge. There are four
health centres in the district that also provide ARVs and ART
care free of charge and with support from the MUWRP. In
the Kayunga Hospital HIV/ART clinic like in all accredited
ART sites in Uganda, patients before initiating ART are
usually required toin addition to othercriteria, disclose their
HIV status to a chosen friend or family member. Such an
individual is known as a treatment supporter and should be
chosen indiscussionwith thepatient,havethepatient’strust,
should be available to go to the preparatory visits with the
patient,andshouldbecommittedtosupportthepatientwith
ART over a long time.
2.2. Study Design and Participants. Ap r o s p e c t i v ec o h o r t
design was employed for this study. It was part of a
project by the Communicable Disease Research Programme
Consortium (COMDIS) in Uganda to identify feasible and
replicable methods of improving medication adherence
for use in the context of resource-constrained settings. It
was conducted under the routine operational programme
conditions ofthe HIV/ARTclinicand was implementedwith
minimum additional inputs, reﬂecting real-life settings. The
study population in this study included adults (18 years and
over) who were receiving treatment at the Kayunga Hospital
HIV/ART clinic. All adult patients visiting the clinic and
had been receiving ART for at least three months as at the
b e g i n n i n go ft h es t u d yp e r i o dw e r ea g r e e a b l et ob ep a r t
of the study and were included. The majority of patients
were receiving a ﬁrst-line ﬁxed dose combination regimen
consisting of Zidovudine, Lamivudine and Nevirapine or
Stavudine, Lamivudine and Nevirapine. Clinic attendance
for their four-weekly reﬁll of ARVs was monitored for this
cohort over a 28-week period. During the study period,
patients received regular health education sessions and
adherence counselling support which was part of the routine
care that the HIV/ART clinic provided and are typical for
Uganda and other HIV/AIDS treatment programmes in
subSaharan Africa. The ethics committee of the Makerere
University Medical School reviewed and approved the study
procedures and data collection instruments. Verbal and
written consents were obtained for all participants.
2.3. Data Collection. Trained adherence workers and
research assistants, all locals in the study area, were used
for data collection. Data was collected on the clients’
sociodemographic proﬁle, type of ART combination
regimen and duration on ART. Clinic attendance for
each client was monitored every four weeks based on the
given clinic appointment dates for ARV reﬁlls (these were
scheduled at four-weekly intervals). Clinic attendance was
categorised into “regular attendance” and “inconsistent
attendance”. Regular clinic attendance was deﬁned as the
patient visiting the clinic for their reﬁlls on the scheduled
appointment dates for the entire study period (also included
clients who attended appointments before the day scheduledAIDS Research and Treatment 3
or those who were late by about three days and had extra
pills to cover this period). “Inconsistent attendance” was
deﬁned as missing one or more clinic appointments (but
not consecutive) for reﬁlls during the study period. A
medication adherence assessment was also conducted at the
same time on each client who reported at the health facility
for their four-weekly reﬁll of ARTs using a clinic-based pill
count. Medication adherence was deﬁned as the percentage
of prescribed medication doses taken during each 4-week
period [26]w i t hl e v e l so f9 5 %a n do v e rb e i n gc a t e g o r i s e d
as “optimal” and levels less than 95% as “suboptimal”.
Adherence using pill count was calculated by dividing
the number of pills actually taken by the number of pills
the client was required to take over the reporting period
multiplied by 100. Full details of how adherence assessment
was conducted have been reported elsewhere [3]. Clients
who missed visits were followed-up and reasons for their
missed visits were ascertained. Data was also collected
on clients who were transferred out, lost to follow up
or died during study period. Deaths reported were the
ones conﬁrmed by the clinic after followup. Those lost to
followup potentially included deaths but which could not be
conﬁrmed because their whereabouts could not be traced
during followup. Loss to followup was deﬁned as missing
more than two consecutive clinic appointments after the
dateoflast attendance [27, 28]. Transferred outwas recorded
for patients who formally transferred to another treatment
centre. Zero medication adherence was awarded to patients
who missed visits and were known not to have collected
medications from the pharmacy and those patients who
were incapacitated or sick and were known not to have taken
their medications.
2.4. Statistical Analysis. Data were entered and analysed
using Statistical Package for the Social Sciences (SPSS) ver-
sion17.0forwindows(SPSSInc.,Chicago,USA).Descriptive
analysis was employed for the basic demographic, ART
treatment characteristics and clinic attendance categories.
Individual mean medication adherence levels using pill
counts were determined for the period of data collection.
The mean medication adherence for the study sample and
proportions of clients achieving adherence levels of 95% and
over were also determined and 95% conﬁdence intervals
(CIs) calculated. Fisher’s exact test was used to deter-
mine the association between clinic attendance for reﬁlls
and medication adherence. Factors associated with optimal
adherence and regular clinic attendance were determined
usingmultivariatelogisticregression analyses. P-values < .05
(two-sided) were considered statistically signiﬁcant. All
results were given as mean (standard deviation (SD)) unless
indicated otherwise.
3.Results
3.1. Demographic Data and Patient Characteristics. Baseline
characteristics of the 392 study participants are shown
in Table 1. Median age was 38 years with 65% of study
participants being female. 73% of clients had only a primary
Table 1:Sociodemographic and treatmentcharacteristics(N=392).
Variables n (%) Median (IQR)
Age (years) 38.0 (32.0–45.0)
Sex
Male 138 (35.2)
Female 254 (64.8)
Educational level
No education 58 (14.8)
Primary 228 (58.2)
Secondary 99 (25.3)
Tertiary 7 (1.8)
Employment
Unemployed 217 (55.4)
Employed 175 (44.6)
Marital status
Single 155 (39.5)
Married 197 (50.3)
Divorced 32 (8.2)
Unmarried partner 8 (2.0)
Time on ARV drugs (years) 2.5 (1.6–3.7)
≤2 147 (37.5)
>2 245 (62.5)
IQR, Interquartile range
Table 2: Summary of clients’clinic attendance during study period
(N = 392).
Clinic Attendance Patterns n (%)
Attended all appointments for reﬁlls
(regular clinic attendance) 361 (92.1)
Missed one visit 24 (6.1)
Missed two or more visits 7 (1.8)
Transferred out∗ 11 (2.8)
Lost to followup∗ 3 (0.8)
Died (conﬁrmed)∗ 1 (0.3)
∗All these clients also had one or more missed visits prior to the recorded
outcome.
education or less. The majority of clients were unemployed
(55%) and had been on ART for more than 2 years (63%).
All clients reported having a treatment supporter but we had
no way of determining if this was still active.
3.2. Clinic Attendance Patterns. A total of 2267 clinic ap-
pointments were scheduled for the 392 clients during the
28-week study period with 31 clients missing 40 clinic visits.
Clinic attendance patterns are shown in Table 2.
Self-reported major reasons cited for missed visits were
travel and ﬁnancial constraints because of the long dis-
tance involved in travelling to the clinic—36 (66.7%) and
forgetfulness—12 (22.2%). Other reasons included being
too ill to come to clinic—3 (5.6%); depression—1 (1.9%);
commitments with work or other activities—1 (1.9%); and
being discouraged from returning because of the long delays
at the clinic—1 (1.9%)4 AIDS Research and Treatment
Table 3: Comparison of clinic attendance with adherence for the
ART treatment cohort.
Optimal
adherence
Suboptimal
adherence Total
Regular clinicattendance 340 21 361
Inconsistent attendance 25 6 31
Total 365 27 392
Table 4: Multivariate logistic regression analysis to determine
predictors of optimal adherence.
Variable OR [95% CI] P
Sex
Female 1.00
Male 0.75 [0.30–1.91] .546
Age (years)
Greater than 35 1.00
Less than or equal to 35 0.75 [0.31–1.82] .529
Education
Educated 1.00
No education 0.32 [0.12–0.85] .022
Employment
Employed 1.00
Unemployed 1.87 [0.81–4.30] .143
Duration on ARVs
More than 2 years 1.00
Less than or equal to 2 years 0.62 [0.27–1.41] .253
Clinic attendance
Regular attendance 1.00
Inconsistent attendance 0.28 [0.10–0.79] .016
OR: odds ratio
3.3. Adherence Levels. Mean medication adherence (95%
CI) was 98.4% (98.1%–98.6%) with 365 (93.1%) of study
participants achieving optimal medication adherence.
3.4. Clinic Attendance and Adherence. Table 3 shows num-
bers of clients and their patterns of clinic attendance
accordingtotheoptimalorsuboptimaladherencecategories.
Of the 31/392 (7.9%) clients whose clinic attendance for
reﬁlls were inconsistent, only 6/31 (19.4%) achieved subop-
timal medication adherence for the entire duration of the
study.
A Fisher’s exact test showed there was a signiﬁcant asso-
ciation between clinic attendance for reﬁlls and medication
adherence (exact P = .013). Clients with regular attendance
were more likely to achieve optimal adherence compared to
clients with inconsistent attendance: (OR = 3.89, 95% CI:
1.48 to 10.25); (risk ratio = 1.20, 95% CI: 0.98 to 1.47);
(risk diﬀerence = 0.15, 95% CI: −0.01 to 0.31). A multi-
variate logistic regression analysis showed that clients whose
visits were inconsistent and those who were not educated
were signiﬁcantly less likely to achieve optimal adherence
(Table 4).
Table 5: Multivariate logistic regression analysis to determine
predictors of regular clinic attendance.
Variable OR [95% CI] P
Sex
Female 1.00
Male 0.47 [0.20–1.08] .075
Age (years)
Greater than 35 1.00
Less than or equal to 35 0.33 [0.15–0.74] .007
Education
Educated 1.00
No education 0.46 [0.17–1.25] .128
Employment
Employed 1.00
Unemployed 1.33 [0.62–2.84] .461
Duration on ARVs
More than 2 years 1.00
Less than or equal to 2 years 1.89 [0.82–4.34] .136
3.5. Predictors of Clinic Attendance. A multivariate logistic
regression analysis showed that those in age category 35
years and below were signiﬁcantly less likely to achieve
regular attendance (Table 5). There were no other signiﬁcant
associations.
4.Discussion
Our ﬁndings show that there is a high level of regular clinic
attendance amongst ART clients for their ARV reﬁlls in
this resource-constrained setting. Of the 392 clients, 92%
were fully attendant during the entire study period. This is
despiteouruseofamorestringent deﬁnitionofregularclinic
attendance—a client attending all scheduled appointments
during the entire study period. Other studies have used less
stringent deﬁnitions such as a client attending greater than
90% of three monthly appointments [24]. Regular clinic
attendance for ARV drugs reﬁlls is important for successful
clinical outcomes in HIV treatment [29]. Park et al. [30]
demonstrated that adherence to clinic visits was associated
with clinical improvement regardless of clinical category
when ART was started. Patients who attend clinic regularly
for their reﬁlls also have the opportunity to be treated
for HIV-related diseases. Timeliness for appointments has
been demonstrated to be positively correlated with better
outcomes amongst patients on ART [14, 15].
In our study, major reasons given for missed visits
included travel and ﬁnancial constraints and forgetful-
ness, which are consistent with ﬁndings reported in other
studies [31, 32]. Other reasons included depression and
commitments with work or other activities. Patients’ social
situation may have a signiﬁcant impact on their ability
to consistently attend their clinic appointments for reﬁlls.
Attendance to clinic appointments will more often not
be regular in an unstable social environment. There is
the need to identify trusted family members, partnersAIDS Research and Treatment 5
and friends as treatment supporters who will assist with
patients’appointmentkeeping,providethemwithemotional
support and may sometimes represent them when they
are too ill to attend the clinic for their reﬁlls. This is a
requirement in all ART-accredited sites in Uganda before
initiating clients on ART but some clients for fear of
stigmatisation will prefer not to disclose their status. It
has been reported that the number of missed visits are
directlyrelated totherateofdisease progression [30].Missed
appointments should trigger concerns about patients at risk
ofdefaulting ontheirtreatment. Morefeasible, practical,and
sustainable ways of providing ART need to be developed to
avoid the issue of missed appointments. Home-based HIV-
care has been shown to be as eﬀective as the facility-based
care and could enable equitable access to HIV treatment,
especially in areas with poor access to care [33]. Mobile
clinics and the setting up of more ART treatment facilities
which are closer to home will help reduce transportation
problems and costs.
Patients on ART treatment in this resource-constrained
setting, take on average 98% of their prescribed ART with
about 93% achieving optimal adherence. These high levels
of ART adherence are broadly consistent with the results of
otherstudiesconductedin such resource-constrained setting
[3, 34–37]. Our study demonstrated that clinic attendance
forreﬁlls was signiﬁcantly associated withmedication adher-
ence with regular clinic attendants being more likely to
achieve optimal adherence. Respondents who missed clinic
appointments for reﬁlls were less likely to achieve optimal
medication adherence. HIV−infected patients who miss
clinic visits may also miss taking their antiretroviral medi-
cations[38, 39]. It is possible that patients who always attend
the clinic on their appointment dates for their reﬁlls may be
the ones more likely to be motivated to be adherent to their
medication regimen. Clients who were not educated were
also less likely to achieve optimal adherence. There were no
associations with other sociodemographic variables. Some
studies have found signiﬁcant associations between good
adherence and male gender and older age [40, 41]b u to t h e r
studies have found increasing age in years as signiﬁcantly
associatedwithsuboptimaladherence[42,43].Generally,the
role of social and demographic characteristics such as race,
gender, age and educational level as predictors of adherence
has produced mostly inconsistent results [43, 44]. Adherence
levels exhibit both intra and interindividual variation [45]
andthemajorityofpeoplewillexhibitlowadherencesomeof
the time [44]. Our study demonstrated that clients under 35
years of age were less likely to be fully attendant which is not
surprising, as youngerpatients are more likely to have higher
nonattendance rates; a ﬁnding which has been reported in
several studies [46, 47]. Male gender and patients with no
education were also less likely to be fully attendant but these
associations were not statistically signiﬁcant. Data from sev-
eralstudiessuggestthatculturalandsociodemographicchar-
acteristics inﬂuence patients’ attendance to clinic appoint-
ments. Israelski et al. [48]d e m o n s t r a t e dt h a tp a t i e n t so f
older age and receiving a higher income were more likely
to keep medical appointments. Catz and colleagues [18]a l s o
reportedthatgreateroutpatientappointmentnonattendance
was associated with younger age, minority status and lower
perceived social support. There is the need for research to
better understand the predictors of clinic attendance, and
then develop and test eﬀective interventions for all patients;
with more intensive intervention in those subsequently
found to miss an appointment (s).
4.1. Study Strengths and Limitations. Though informative,
our study had several limitations which merit consideration.
We were not able to corroborate attendance and adherence
monitoring using pill counts with more objective indicators
such as immunological, virological or clinical outcomes
because of ﬁnancial constraints particularly the cost of
additional laboratory monitoring in this setting. Pill counts
are commonly used to measure medication in research, they
have a higher level of accuracy compared to patient self-
reports and can be conducted when the patient returns to
the clinic/pharmacy to obtain a reﬁll [49]. But like self-
reports, pill counts also tend to overestimate adherence
[50, 51], often due to “pill dumping” [52]. They are too
time-consuming and computationally complex for most
clinical purposes and like most other adherence measures,
the main drawback is that ingestion is not conﬁrmed. The
clinic-based pill count measure though not very objective
compared to Medication Event Monitoring System (MEMS)
caps and HIV viral loads, it has been reported to be
correlated with viral loads [26, 34, 53]. Farley and colleagues
[11] also demonstrated that appointment keeping behaviour
correlated with virologic response. There were potentially
important variables such as income of respondents, distance
from the clinic, partner HIV testing and status, stage of HIV
disease and coexisting opportunistic infections, which could
aﬀect clinic attendance and adherence to medications but
were not presented in our multivariate analyses because of
the unavailability of such data. The data was derived from
a single site and so may not be generalisable to the whole
country or elsewhere in subSaharan Africa. Our sample
size was small with a followup period of 28 weeks; larger
studies and longer followup periods may be required to
conﬁrm our results. An additional limitation is that there
was the possibility of a potentially biased study population;
it may be that we collected data from a cohort of more
highly motivated people with regular clinic attendance and
high adherence who gained the most from ART. Despite
the various limitations, our study replicated the typical
conditions under which treatment and care is delivered in
such resource-poor settings. The beneﬁts observed in this
study may therefore be replicated in other sites. During the
observationperiod,antiretroviral medicationswerealwaysin
stock at the study site.
4.2. Conclusions. Regular clinical attendance for medication
reﬁlls and optimal adherence to ART have a critical inﬂuence
on outcomes of ART. Continuity of care is essential to
ensure the maximum health beneﬁts of ART. There is a
need to develop interventions which will improve clinic
attendance among clients. Similarly, there is the need to
develop feasible, practical, reliable and inexpensive methods6 AIDS Research and Treatment
of contacting and recalling patients who miss clinic appoint-
ments. Good medication adherence does not only entail
compliance to medications; it also includes attendance at
scheduled appointments [54]. Clinic attendance monitoring
may be combined with adherence measures and clinic
outcomes monitoring which will improve the objectivity of
adherence measurements. A simple and standard approach
for recording attendance and identifying patients who miss
appointments such as a clinic appointment log, can help
health facilities identify the problems and develop the
appropriate interventions to improve clinic attendance. This
approach has been traditionally used in TB registers, where
the right hand side of the register is for recording the
scheduled appointment date, and then above this, the actual
date of attendance. Monitoring of clinic attendance may
be an objective and eﬀective measure and could be a
useful adjunct to adherence measures and monitoring of
clinical outcomes. Where human resource constraints and
large numbers of ART patients do not allow pill counts
or other time consuming measures, then monitoring clinic
attendance for reﬁlls and acting on missed appointments
may be an eﬀective proxy measure.
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